Back
Gilead Sciences 10K Form
Sell
30
GILD
Gilead Sciences
Last Price:
67.88
Seasonality Move:
6.01%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-08 | 10Q | GILD/Gilead Sciences Quarterly |
| 2024-02-23 | 10K | GILD/Gilead Sciences Annual |
| 2023-11-07 | 10Q | GILD/Gilead Sciences Quarterly |
| 2023-08-04 | 10Q | GILD/Gilead Sciences Quarterly |
| 2023-05-03 | 10Q | GILD/Gilead Sciences Quarterly |
| 2023-02-22 | 10K | GILD/Gilead Sciences Annual |
Receive GILD News And Ratings
See the #1 stock for the next 7 days that we like better than GILD
GILD Financial Statistics
Sales & Book Value
| Annual Sales: | $27.12B |
|---|---|
| Cash Flow: | $2.11B |
| Price / Cash Flow: | 10.64 |
| Annual Sales: | $14.07 |
| Price / Book: | 4.76 |
Profitability
| EPS (TTM): | 0.36000 |
|---|---|
| Net Income (TTM): | $484M |
| Gross Margin: | $20.62B |
| Return on Equity: | 2.32% |
| Return on Assets: | 0.79% |
Gilead Sciences Earnings Forecast
Key Gilead Sciences Financial Ratios
- The Gross Profit Margin over the past 33 years for GILD is 76.04%.
- The Selling, General & Administrative Expenses for GILD have been equal to 22.46% of Gross Profit Margin.
- The Research & Development expenses have been 21.09% of Revenue.
- The Interest Expense is 16.66% of Operating Income.
- The Net Earning history of GILD is 20.89% of Total Revenues.
- Per Share Earnings over the last 33 years have been positive in 19 years.
Gilead Sciences Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | GILD |
| CUSIP: | 375558 |
| Website: | gilead.com |
Debt
| Debt-to-Equity Ratio: | 1.44 |
|---|---|
| Current Ratio: | 1.08 |
| Quick Ratio: | 0.72 |
Price-to-Earnings
| Trailing P/E Ratio: | 14.89 |
|---|---|
| Forward P/E Ratio: | 9.35 |
GILD Technical Analysis vs Fundamental Analysis
Sell
30
Gilead Sciences (GILD)
is a Sell
Is Gilead Sciences a Buy or a Sell?
-
Gilead Sciences stock is rated a Sell
The current Gilead Sciences [GILD] share price is $67.01. The Score for GILD is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.